Survival Following Non Surgical Treatments for Oral Cancer: a Single Institutional Result

Larizadeh, Mohammad Hasan; Shabani, Mohammad

doi:10.7314/apjcp.2012.13.8.4133

Cited by 11 publications

(20 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…All studies 29 , 34 , 36–38 , 45 , 49 used the 2 or 3 drug regimens CT, and the main outcome reported was OS ( Table 2 ).…”

Section: Resultsmentioning

confidence: 99%

Therapeutic Options in Unresectable Oral Squamous Cell Carcinoma: A Systematic Review

Anaya¹,

Amador²,

Acosta³

2021

CMAR

View full text Add to dashboard Cite

Purpose This review describes the current scientific evidence of therapeutic options in unresectable oral squamous cell carcinoma. Methods This study followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). We searched MEDLINE (Via PubMed) to identify studies assessing treatments for unresectable oral squamous cell carcinoma. The methodological quality assessment of the included studies was performed using the Joanna Briggs Institute (JBI) checklist tool. The evidence was organized and presented using tables and narrative synthesis. Results Thirty-three studies met the eligibility criteria. Most studies had an observational design. The sample size varied from 16 to 916 participants. The methodology quality of the included studies ranged from 2.5 to 10 using the JBI tool. Overall, the optimal treatment of patients with unresectable oral cancer is challenging, so there is a sprinkling of studies assessing a variety of therapeutic options, such as radiotherapy, chemotherapy, concurrent chemoradiotherapy, immunotherapy, targeted therapy plus chemotherapy or radiotherapy, and gene therapy plus chemotherapy. Conclusion There is lacking evidence about the benefits of some therapeutic options for unresectable oral squamous cell carcinoma. Overall, these patients can be treated using a multimodal approach such as concurrent chemoradiotherapy or induction chemotherapy followed by chemoradiotherapy, which have shown good clinical outcomes. However, other options could be considered depending on the assessment of risk/benefits, tumor extension, and patient values and preferences.

show abstract

“…All studies 29 , 34 , 36–38 , 45 , 49 used the 2 or 3 drug regimens CT, and the main outcome reported was OS ( Table 2 ).…”

Section: Resultsmentioning

confidence: 99%

Therapeutic Options in Unresectable Oral Squamous Cell Carcinoma: A Systematic Review

Anaya¹,

Amador²,

Acosta³

2021

CMAR

View full text Add to dashboard Cite

show abstract

“…Adding chemotherapy to the conventional treatment has been used to improve survival, reduce metastasis, and increase organ preservation. Chemotherapy is used in 3 different settings: induction therapy, concomitant chemo-radiotherapy, and sequential treatment, which consists induction chemotherapy followed by concomitant chemo-radiotherapy (1)(2)(3)(4). Recently, the incorporation of cetuximab to induction and/or concomitant phase of chemoradiation has been an area of interest (5)(6)(7)(8).…”

Section: Contextmentioning

confidence: 99%

Cetuximab for Squamous Cell Carcinoma of the Head and Neck

Larizadeh

2017

Int J Cancer Manag

Self Cite

View full text Add to dashboard Cite

Context: Treatment outcome for locally advanced squamous cell carcinoma of the head and neck is poor. Recently, anti-epidermal growth factor monoclonal antibodies, such as cetuximab have been used to improve outcome. Evidence Acquisition: Medline, EMBASE, and SCOPUS were searched to identify published studies that evaluated cetuximab for loco regionally advanced and metastatic/recurrent squamous cell carcinoma of head and neck. Only published studies in English between 1990 and 2016 were included. Results: Cetuximab may be administered concomitantly with radiation alone or in combination with chemotherapy during the induction phase of sequential modalities. Also, it has been used in combination with chemotherapy as first line or second line for treatment of metastatic/recurrent patients. Conclusions: Cetuximab can be incorporated at some points in the course of treatment of patients with squamous cell carcinoma of the head and neck. The best protocols and the appropriate patients remain to be defined.

show abstract

“…Furthermore, according to the National Cancer Institute, oral cancer accounted for 2.9% and 1.6% of the incidence and mortality of all cancers, respectively, in 2017 in the United States. The five-year survival rate of patients with oral cancer decreases significantly with increasing stage, ranging from 77.7% to 32.8%, and the survival rate drops to 10% owing to recurrence and metastasis [ 1 , 2 , 3 ]. The common therapeutic procedure in oral cancer is first the administration of curable treatments, such as surgery, for early stage oral cancer and palliative treatments, including radiotherapy, chemotherapy, target therapy and combination treatments, for nonsurgical or advanced cases of oral cancer [ 4 ].The current treatment not clearly improves survival benefits of patients due to the drug resistance, tolerance to chemo-drug toxicity and high recurrent rate.…”

Section: Introductionmentioning

confidence: 99%

Extract of Juniperus indica Bertol Synergizes with Cisplatin to Inhibit Oral Cancer Cell Growth via Repression of Cell Cycle Progression and Activation of the Caspase Cascade

et al. 2020

View full text Add to dashboard Cite

Oral cancer—a type of head and neck cancer—is estimated to be the fifth most common cancer in Taiwan. However, efficacious therapies for oral cancer are still lacking due to drug resistance and recurrence. Consequently, the identification of new anticancer agents for clinical treatment is needed. Juniperus indica Bertol is a plant of the Juniperus genus often used as a treatment in traditional medicine due to its anti-inflammatory, antibacterial and diuretic functions. The biofunctions of Juniperus indica Bertol including its anticancer potential, have not been fully explored. As a result, the aim of this research was to investigate the anticancer activity of Juniperus indica Bertol extract (JIB extract) and determine whether JIB extract has synergistic effects with cisplatin in oral cancer. These results are the first to demonstrate that JIB extract exhibits anticancer capacity and synergizes with cisplatin to treat oral cancer. Our findings indicate that JIB extract has a potential to develop anticancer agent and chemo therapeutic adjuvant for oral cancer.

show abstract

Survival Following Non Surgical Treatments for Oral Cancer: a Single Institutional Result

Cited by 11 publications

References 22 publications

Therapeutic Options in Unresectable Oral Squamous Cell Carcinoma: A Systematic Review

Therapeutic Options in Unresectable Oral Squamous Cell Carcinoma: A Systematic Review

Cetuximab for Squamous Cell Carcinoma of the Head and Neck

Extract of Juniperus indica Bertol Synergizes with Cisplatin to Inhibit Oral Cancer Cell Growth via Repression of Cell Cycle Progression and Activation of the Caspase Cascade

Contact Info

Product

Resources

About